JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2025, none posted yet
Counts until it's fixed
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 3
- Patients
- 587 (final count)
- Started
- Oct 14, 2021
- Main results expected
- Aug 1, 2025
- Fully finished
- Sep 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-08-01, no fading
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05083169 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC